| Cash Flow | 2026-06-30 |
|---|---|
| Net loss | -58,957 |
| Depreciation of equipment | 11 |
| Stock-based compensation | 9,278 |
| Amortization of right of use lease asset | 68 |
| Prepaid expenses and other current assets | 274 |
| Other assets, noncurrent | 23 |
| Accounts payable | 3,038 |
| Accrued expenses and other current liabilities | 6,494 |
| Operating lease liabilities | -67 |
| Paramora warrant obligation | 9,527 |
| Related party accounts payable and other current liabilities | -11,559 |
| Other liabilities, noncurrent | -1 |
| Net cash used in operating activities | -42,465 |
| Issuance of stock in connection with offerings | 346,217 |
| Issuance costs in connection with offerings | 21,441 |
| Proceeds from exercise of stock options | 650 |
| Net cash provided by financing activities | 325,426 |
| Net increase (decrease) in cash and cash equivalents | 282,961 |
| Effect of exchange rate changes on cash and cash equivalents | -70 |
| Cash and cash equivalents, beginning of year | 257,624 |
| Cash and cash equivalents, end of year | 540,515 |
Damora Therapeutics, Inc. (DMRA)
Damora Therapeutics, Inc. (DMRA)